IP Library › Granted Patent US 10,512,616
Granted Patent B2
US 10,512,616 · App. 15/844,459 · Granted Dec 24, 2019

Composition to enhance the bioavailability of curcumin

Inventor: Benny Antony (Angamaly, IN)
Assignee: Arjuna Natural Private Limited
A61K31/12A61K36/9066A61K47/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,512,616
App. No.
15/844,459
Granted
Dec 24, 2019
Kind
B2
Abstract

A composition for enhanced bioavailability of curcumin including purified curcuminoid and purified essential oil of turmeric. A method to prepare a composition for enhanced bioavailability of curcumin having purified curcuminoid and purified essential oil of turmeric.

Claims (8)

1. A method of obtaining a blood curcumin concentration of about 92 ng/g in a human subject, the method comprising administering a composition for enhanced bioavailability of curcumin to the human subject, wherein the composition for enhanced bioavailability of curcumin comprises a curcuminoid mixture and the essential oil of turmeric, wherein a weight ratio of the curcuminoid mixture to the added essential oil of turmeric ranges from about 1:3 to about 99:1, wherein the curcuminoid mixture consists of curcumin, demethoxycurcumin and bisdemethoxycurcumin, and wherein the essential oil of turmeric comprises about 45% ar-turmerone.

2. The method of claim 1 , wherein the blood curcumin concentration of about 92 ng/g in the human subject is reached about 3 hours after administering the composition for enhanced bioavailability of curcumin.

3. A method of enhancing bioavailability of curcumin in a human subject, the method comprising administering a composition for enhanced bioavailability of curcumin, wherein the composition for enhanced bioavailability of curcumin comprises a curcuminoid mixture and the essential oil of turmeric, wherein a weight ratio of the curcuminoid mixture to the added essential oil of turmeric ranges from about 1:3 to about 99:1, wherein the curcuminoid mixture consists of curcumin, demethoxycurcumin and bisdemethoxycurcumin, and wherein the essential oil of turmeric comprises about 45% ar-turmerone.

4. The method of enhancing bioavailability of curcumin in the human subject of claim 3 , wherein administering the composition for enhanced bioavailability of curcumin results in about 5-fold to about 16-fold enhancement of curcumin concentration in the human subject as compared to administering a composition comprising the curcuminoid mixture without the added essential oil of turmeric.

5. The method of claim 3 , wherein a blood curcumin concentration of about 92 ng/g is observed at about 3 hours following administration of the composition for enhanced bioavailability of curcumin.

6. The method of claim 3 , wherein a blood curcumin concentration of about 5 ng/g is observed at about 8 hours following administration of the composition for enhanced bioavailability of curcumin.

7. A method of obtaining a blood curcumin concentration of about 5 ng/g in a human subject, the method comprising administering a composition for enhanced bioavailability of curcumin to the human subject, wherein the composition for enhanced bioavailability of curcumin comprises a curcuminoid mixture and the essential oil of turmeric, wherein a weight ratio of the curcuminoid mixture to the added essential oil of turmeric ranges from about 1:3 to about 99:1, wherein the curcuminoid mixture consists of curcumin, demethoxycurcumin and bisdemethoxycurcumin, and wherein the essential oil of turmeric comprises about 45% ar-turmerone.

8. The method of claim 7 , wherein the blood curcumin concentration of about 5 ng/g in the human subject is reached about 8 hours after administering the composition for enhanced bioavailability of curcumin.

Continuity (8)
Continuation 14623608 · Feb 17, 2015
Division 13674249 · Nov 12, 2012
Division 13506572 · Apr 30, 2012
Division 12926980 · Dec 21, 2010
Division 12073864 · Mar 11, 2008
Continuation In Part 11635599 · Dec 8, 2006
Continuation PCTIN2005000176 · May 30, 2005
Related Publication 20180104339A1 · Apr 19, 2018
Cited By (1)
US 12,251,415